Ebselen: prospective therapy for cerebral ischaemia.

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Stroke involves complex destructive mechanisms like oxidative stress and inflammation.
• Ebselen (2-phenyl-1, 2-benzisoselenazol-3(2H)-one) mimics glutathione peroxidase and exhibits antioxidant and anti-inflammatory properties.
• Ebselen's low toxicity is attributed to its unique metabolic pathway, which retains selenium within the ring structure.

Purpose of the Study:

• To evaluate the efficacy and safety of ebselen for stroke treatment.
• To investigate the molecular mechanisms underlying ebselen's neuroprotective effects.
• To assess the impact of treatment initiation timing on patient outcomes.

Main Methods:

• In vitro studies using isolated cells and organs to assess protection against oxidative challenge.
• In vivo studies in animal models (rats and dogs) to evaluate inhibition of vasospasm and tissue damage.
• Randomized, placebo-controlled, double-blind clinical trials in patients with acute ischemic stroke and subarachnoid hemorrhage.

Main Results:

• Ebselen demonstrated significant protection against oxidative stress in various experimental models.
• Animal studies showed ebselen inhibited vasospasm and tissue damage, correlating with its antioxidant effects.
• Clinical trials indicated ebselen significantly improved outcomes in patients with acute ischemic stroke, particularly when administered early.

Conclusions:

• Ebselen possesses significant anti-inflammatory and antioxidant properties beneficial for stroke treatment.
• The drug's low toxicity and demonstrated efficacy in preclinical and clinical studies support its therapeutic potential.
• Early initiation of ebselen treatment is crucial for maximizing benefits in patients experiencing acute ischemic stroke.